

# Neuropathologie WiSe 24/25

## Neurodegenerative Erkrankungen

Prof. Dr. Ruth Stassart

Paul-Flechsig-Institut - Zentrum für Neuropathologie und Hirnforschung




- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson

- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson


# Was sind neurodegenerative Erkrankungen?

# Was sind neurodegenerative Erkrankungen?

- Progrediente neuronale Dysfunktion und neuronaler Verlust
- Sehr unterschiedliche Definitionen und Klassifikationen




Wilson et al., Cell 2023



Wilson et al., Cell 2023

**Klinisch:**  
Demenz vs  
Motorische Störung






Wilson et al., Cell 2023

## Klinisch: Demenz vs Motorische Störung


Movement disorders
Akinetic and rigid
Hyperkinetic
Ataxic
Motor neuron disorders
Cognitive disturbance (dementia)
Temporal and parietal degenerations
Frontotemporal degenerations
Multifocal degenerations



# Selektiver Nervenzellverlust in Neurodegeneration



Gan, L., Cookson, M.R., Petrucelli, L. et al. (2018) Nat Neurosci 21, 1300–1309




Wilson et al., Cell 2023


**Klinisch:**  
Demenz vs  
Motorische Störung

**Pathophysiologisch:**  
Trauma  
Entzündung  
Demyelinisierung  
Proteinaggregate  
Genetisch  
Betroffene Neurone  
und Hirnregionen


# Neurodegenerative Erkrankungen: Aggregopathien





Alzheimer's plaques and tangles




Parkinson's Lewy bodies



Huntington's intranuclear inclusions




Prion amyloid plaques




Amyotrophic lateral sclerosis aggregates






# Was sind neurodegenerative Erkrankungen?



# Was sind neurodegenerative Erkrankungen?


NDD hallmarks at the subcellular level



Wilson et al., Cell 2023

- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson





**Auguste Deter: 1850-1906**

„Über eine  
eigenartige  
Erkrankung der  
Hirnrinde“

Klinik:  
Zeitlich-/räumlicher Orientierungsverlust  
Vergesslichkeit, Aphasie, Paraphrasien

## Demenz nach ICD 10:

Störung des Gedächtnisses und mindestens einer weiteren kognitiven Teilleistung  
Länger als 6 Monate anhaltend  
Chronisch progredient  
Bewusstseinsstörung muss ausgeschlossen sein  
Störung der sozialen und/oder beruflichen Funktion

Ursachenspektrum  
demenzielles Syndrom

### Primär neurodegenerativ:

M. Alzheimer >50 % aller Demenzen  
Frontotemporale Demenz  
M. Parkinson  
Lewy-Body-Demenz  
Chorea Huntington  
Progressive nukleäre Blickparese  
**Vaskulär** ~ 20% aller Demenzen


### Sekundär z.B.:

Hypox. Hirnschaden  
Tumor/Blutung/Trauma  
Entzündlich  
Metabolisch/ Toxisch  
Normaldruckhydrozephalus





nicht jedes demenzielle Syndrom ist durch eine neurodegenerative Erkrankung bedingt

Neurodegenerative Erkrankungen gehen häufig mit demenziellem Syndrom einher




## Äußere und innere- Hirnatrophie




<https://neuropathology-web.org/chapter9/chapter9bAD.html#ad>












**Intrazelluläre  
neurofibrilläre Tangles  
(NFT)**



**Extrazelluläre  
Neuritische  
Plaques (NPs)**




**Intrazelluläre  
neurofibrilläre Tangles  
(NFT)**




**Extrazelluläre  
Neuritische  
Plaques (NPs)**






**Extrazelluläre  
Neuritische  
Plaques (NPs)**

## Amyloidablagerungen




**Extrazelluläre  
Neuritische  
Plaques (NPs)**





APP = transmembranöses Glykoprotein  
Gen auf Chromosom 21

Funktion unklar > Oberflächenrezeptor mit  
Funktionen in der Zell-Zell und Zell-Matrix Interaktion


## Amyloidablagerungen





A $\beta$  Peptid Fragmente: insb. 40 oder 42 Aminosäuren lang. A $\beta$  Peptide in Plaques: hauptsächlich 42-residue Form of A $\beta$  (A $\beta$ 42)









Plaque stages: poor correlation with clinical severity of dementia



**Stage A:** Low density of plaques in neocortex, especially frontal, temporal and occipital lobes



**Stage B:** Plaques present in neocortical association areas with moderate hippocampal involvement




**Stage C:** Plaques present in primary sensory and motor areas in addition to other cortical areas

Mild


Moderate

Severe


















**Intrazelluläre  
neurofibrilläre Tangles  
(NFT)**




**Extrazelluläre  
Neuritische  
Plaques (NPs)**








**Early stage:** There is accumulation of tau protein in neurons but in a dispersed form detectable only by immunohistochemistry for tau protein. There may be perinuclear accentuation of immunoreactivity. Silver staining does not reveal any abnormality.



**Established stage:** Tau protein is aggregated into paired helical filaments as well as a smaller number of straight filaments. There is ubiquitination of some of the tau protein in tangles rendering them immunoreactive for ubiquitin. Silver staining reveals classical tangles.

**Late stage:** There is death of the neuron and removal of cell debris by local phagocytes. The tangle structure remains as an eosinophilic extracellular 'tombstone' or ghost tangle. With time there is progressive loss of tau-protein immunoreactivity. A $\beta$ -peptide is later deposited around these structures and there is infiltration by astroglial processes making these NFTs apparently immunoreactive for GFAP.



Tau protein
  Neuron

A $\beta$


## Biologie des Tau-Proteins

Tau-Protein:  
Mikrotubuli- assoziiertes Protein  
und wichtig für die Funktionalität  
des Zytoskeletts

M. Alzheimer: Tau-Protein  
hyperphosphoryliert

Verdrängung von Zellorganellen  
axonaler Transport ↓  
Zytoplasmatische Zirkulation ↓


**Tangle stages: good correlation with clinical severity ratings**



**TRANSENTORHINAL**  
(Clinically asymptomatic)

**Stage I:** NFTs and NTs in small density, confined to transentorhinal cortex in pre- $\alpha$  cells.

**Stage II:** Tangles present in moderate density in pre- $\alpha$  cells of entorhinal cortex. Small numbers develop in CA1 region of hippocampus




**LIMBIC**  
(Incipient AD)

**Stage III:** There are modest numbers of NFTs and NTs throughout CA1 and in pyramidal cells in the subiculum. Small numbers appear in the fusiform gyrus lateral to the transentorhinal cortex as well as in the nucleus basalis of Meynert and amygdaloid complex.

There is now severe involvement of pre- $\alpha$  cells with neuronal loss and gliosis

**Stage IV:** Severe involvement of areas affected in stage 3. Large numbers of ghost tangles in entorhinal and transentorhinal regions. Mild involvement of isocortex with sparing of primary sensory and motor cortices.




**ISOCORTICAL**  
(Symptomatic AD)


**Stage V:** Tangles in all sectors of hippocampus and subiculum. Widespread, moderate to severe isocortical involvement but still relative sparing of primary sensory and motor cortices. Tangles in claustrum, thalamus, hypothalamus. Ghost tangles with neuronal loss and astrocytic gliosis involving pre- $\alpha$  cells, CA1, antero-dorsal thalamic nucleus.

**Stage VI:** Increased densities of tangles in regions affected in earlier stages. Tangles in dentate granule cell layer. Marked involvement of claustrum, thalamus, hypothalamus, substantia nigra





**Extrazelluläre  
Neuritische  
Plaques (NPs)**



**Intrazelluläre  
neurofibrilläre Tangles  
(NFT)**

Gemeinsame Endstrecke:  
Neuronale Degeneration/ Untergang, Verlust von Synapsen, Hirnatrophie,  
Hydrocephalus e vacuo

# Genetik

## **Early onset (vor dem 65. Lebensjahr)**

### **Selten (~7%) und oft familiär**

Mutationen im APP (Amyloid Precursor Protein) (21q)


Mutationen in PSN1 (Presenilin 1) (14q23.3)

Mutationen in PSN2 (Presenilin 2) (1q13)




## **Late onset (nach dem 65. Lebensjahr)**

### **Häufig und nicht familiär**




APOE e4 (19q13.2)









- Klinische Symptomatik
  - äußere- und innere Hirnatrophie, verm. Hirngewicht
  - Extrazelluläre Ablagerung von neuritischen Plaques; (NPs) Cerebrale Amyloidangiopathie (CAA)
  - Intrazelluläre Akkumulation von Tau-Protein in Form von neurofibrillären Tangles (NFT)
  - Neuronaler Degeneration und Nervenzellverlust, Gliose, granulovakuoläre Degeneration, Hirano-Körperchen



Postmortale Diagnostik kann zur Ursachenklärung der klinischen Symptomatik beitragen


- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson




- Humboldt* 1809
- Humboldt* 1824
- Humboldt* 1827
- Humboldt* 1830
- Humboldt* 1831
- Humboldt* 1834

[https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.uimmed.de%2Fimages%2Fdownload%2Fthema\\_des\\_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8iRuuJQJFhTR6\\_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=CCAQjRxfwoT0lk3CSanudCFQAAAAAABAD](https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.uimmed.de%2Fimages%2Fdownload%2Fthema_des_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8iRuuJQJFhTR6_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=CCAQjRxfwoT0lk3CSanudCFQAAAAAABAD)  
[https://www.t-online.de/sport/boxen/id\\_78028822/nod-von-muhammad-ali-sprecher-nennt-die-todesursache.html](https://www.t-online.de/sport/boxen/id_78028822/nod-von-muhammad-ali-sprecher-nennt-die-todesursache.html)






**T**remor  
**R**igor  
**A**kinetik  
**P**osturale Instabilität



- Handwritten signature* 1809
- Handwritten signature* 1824
- Handwritten signature* 1827
- Handwritten signature* 1830
- Handwritten signature* 1831
- Handwritten signature* 1834


Epidemiologie: Häufigkeitsgipfel 50.-60. Lebensjahr, m=f, zu 70% idiopathisch

[https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.nlm.nih.gov%2Fimg%2Fdownload%2Fimg\\_des\\_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8RuuJQJFhTR6\\_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=DCAJQjxqf'wot'Gik%3DSanuDFQAAAAAABAD](https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.nlm.nih.gov%2Fimg%2Fdownload%2Fimg_des_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8RuuJQJFhTR6_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=DCAJQjxqf'wot'Gik%3DSanuDFQAAAAAABAD)  
[https://www.t-online.de/sport/boxen/id\\_78028822.tod-von-muhammad-ali-sprecher-nennt-die-todesursache.html](https://www.t-online.de/sport/boxen/id_78028822.tod-von-muhammad-ali-sprecher-nennt-die-todesursache.html)



Verlust neuromelaninhaltiger dopaminerges  
Neurone der Substantia nigra

# Pathophysiologie des M. Parkinsons





**Hemmende Wirkung der SN auf die Basalganglienschleife entfällt**

**Enthemmte Basalganglienschleife hemmt den Thalamus**

**Autonome Störungen (Vaguskerne, sympathische Ganglien)**



## Basalganglienschleife


D1 Aktivierung : Direkter Weg  
D2 Aktivierung und Hemmung des STN: Indirekter Weg



[https://de.wikipedia.org/wiki/Parkinson-Krankheit#/media/Datei:Parkinson\\_-\\_Ablauf\\_auf\\_funktioneller\\_Ebene.svg](https://de.wikipedia.org/wiki/Parkinson-Krankheit#/media/Datei:Parkinson_-_Ablauf_auf_funktioneller_Ebene.svg)








3 Synucleine:

$\alpha$ -Synuclein (chr.4)  
 $\beta$ -Synuclein (chr.5)  
 $\gamma$ -Synuclein (chr.10)


$\alpha$ -Synuclein als synaptisches lösliches Protein in Nervenzellen, Bildung von Membrankanälen, Regulation der Dopaminausschüttung

→Lewy-Körperchen,  
neurotoxische Wirkung,  
Nervenzelluntergang











- Ausgeprägter Verlust melanin-  
pigmentierter, dopaminerg  
Nervenzellen in der Substantia nigra



- Konzentrische hyaline Einschlüsse  
(Lewy-Körper) in den pigmentierten  
Nervenzellen.



- Gliose und melaninhaltige  
Makrophagen



## Genetische Formen

Idiopathisches (M. Parkinson)

Sekundäre Parkinsonsyndrome



-Medikamente: typ.  
Antipsychotica, Lithium,  
Valproat, Metoclopramid  
- Traumatisch, Tumor, toxisch  
(CO, Mangan), metabolisch  
(M.Wilson)

Atypische Parkinsonsyndrome

Multisystematrophie  
Lewy-Body-Demenz  
Progressive supr. Blickparese  
Kortikobasale Degeneration

Postmortale Diagnostik zur  
Diagnosesicherung und/oder  
weiteren Einordnung



# Synukleinopathien

## Lewy Body Erkrankungen

Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs $\geq 1$ year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia

## Epidemiologie:

Prävalenz 0,4% der über 65 jährigen  
Häufigstes atypisches Parkinsonsyndrom

## Klinik:

Bradykinese/Rigor mit  
**führend neuropsychiatrische** Symptome:  
fluktuierend kognitive Defizite  
akustische/visuelle Halluzinationen  
Wahnhafte Episoden  
Depression und Angststörung




# Synukleinopathien

## Lewy Body Erkrankungen

Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs $\geq 1$ year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia

## Multisystematrophie

*Gliale Einschlüsse von alpha-Synuklein*





# Synukleinopathien

## Lewy Body Erkrankungen


Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs $\geq 1$ year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia










## Multisystematrophie

*Gliale Einschlüsse von alpha-Synuklein*

MSA – P: Parkinson Symptomatik im Vordergrund  
 MSA – C: cerebelläre Symptomatik im Vordergrund

Olivopontocerebellar atrophy (OPCA)  
 Shy-Drager syndrome  
 Striatonigral degeneration.




	$\alpha$ -syn strains	leading $\alpha$ -syn inclusion pathology	main areas of neuronal loss
classical $\alpha$ -synucleinopathies	PD 	LB 	 - substantia nigra pars compacta
	DLB 	LB 	 - neocortex - substantia nigra pars compacta
	MSA 	GCI 	 - SND - OPCA - brainstem nuclei - autonomic nuclei in the spinal cord

# Die Herausforderung der Neurodegenerativen Erkrankungen

Prävalenz M. Alzheimer	
65-69	1%
70-74	2%
75-79	4%
80-84	8%
über 85	20% - 50%

Altersstruktur der Bevölkerung in Deutschland, 1950–2060



\* Ergebnis der aktualisierten 13. koordinierten Bevölkerungsvorausberechnung (Variante 2-A)  
Datenquelle: Statistisches Bundesamt

© BiB 2018 / demografie-portal.de

## Neurodegenerative Erkrankungen und Demenz 2060?



- Neurodegeneration mit abnormer Proteinablagerung assoziiert
- Neurodegenerative Erkrankungen gehen häufig mit demenziellem Syndrom einher, ABER
- Nicht jedes demenzielles Syndrom ist durch neurodegenerative Erkrankung bedingt
- Histopathologie M. Alzheimer und M. Parkinson
- Postmortale Diagnostik zur Diagnosesicherung und weiteren Einordnung

## Vielen Dank für Ihre Aufmerksamkeit



Bei Fragen, Anmerkungen, Lob/ Kritik:

[Ruth.Stassart@medizin.uni-leipzig.de](mailto:Ruth.Stassart@medizin.uni-leipzig.de)